Zika DNA vaccine shows promise in early trial

News Hour:

An investigational synthetic DNA vaccine (GLS-5700) seems to prompt an immune response against the Zika virus, but researchers caution that more data are needed on the vaccine’s long-term safety and efficacy, according to a phase 1, industry-supported trial in the New England Journal of Medicine.

Forty healthy adults received 1 or 2 mg of the vaccine at baseline, 4 weeks, and 12 weeks. Injections were followed by electroporation (use of a pulsed electric field to introduce the DNA into cells).

At 14 weeks, all patients had Zika-specific binding antibodies. Roughly 70% of the serum samples had 90% inhibition of Zika infection.

Next, mice were injected with the post-vaccination serum and then given a lethal dose of Zika; 92% survived. The authors write: “This finding suggests that the antibody response generated by the vaccine was protective in this infection model.”

Have your say, we value it!

wise people got already engaged

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
Scroll Up